title: Cyclin D1 gene G870A variants and primary brain tumors.
abstract: Alterations of cyclin D1, one of the main regulators of the cell cycle, are known to be involved in various cancers. The CCDN1 G870A polymorphism causes production of a truncated variant with a shorter half-life and thus thought to impact the regulatory effect of CCDN1. The aim of the present study was to contribute to existing results to help to determine the prognostic value of this specific gene variant and evaluate the role of CCDN1 G870A polymorphism in brain cancer susceptibility. A Turkish study group including 99 patients with primary brain tumors and 155 healthy controls were examined. Genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism analysis. The CCDN1 genotype frequencies in meningioma, glioma and control cases were not significantly different (p>0.05). No significant association was detected according to clinical parameters or tumor characteristics; however, a higher frequency of AG genotype was recorded within patients with astrocytic or oligoastrocytic tumors. A significant association between AG genotype and gliobilastoma multiforme (GBM) was recorded within the patients with glial tumors (p value=0.048 OR: 1.87 CI% 1.010-3.463). According to tumor characteristics, no statistically significant difference was detected within astrocytic, oligoasltrocytic tumors and oligodentrioglias. However, patients with astrocytic astrocytic or oligoastrocytic tumors showed a higher frequency of AG genotype (50%) when compared to those with oligodendrioglial tumors (27.3%). Our results indicate a possible relation between GBM formation and CCDN1 genotype.
authors.affiliation: Department of Molecular Medicine, Institute of Experimental Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey. umz67@yahoo.com
authors.forename: Umit
authors.initials: U
authors.lastname: Zeybek
authors.forename: Ilhan
authors.initials: I
authors.lastname: Yaylim
authors.forename: Nazli Ezgi
authors.initials: NE
authors.lastname: Ozkan
authors.forename: Gurbet
authors.initials: G
authors.lastname: Korkmaz
authors.forename: Saime
authors.initials: S
authors.lastname: Turan
authors.forename: Didem
authors.initials: D
authors.lastname: Kafadar
authors.forename: Canan
authors.initials: C
authors.lastname: Cacina
authors.forename: Ali Metin
authors.initials: AM
authors.lastname: Kafadar
mesh_terms: D000328:Adult; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D019938:Cyclin D1 / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005910:Glioma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000235:genetics* / Q000473:pathology; D008579:Meningioma / Q000235:genetics* / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics*; D012150:Polymorphism, Restriction Fragment Length; D011379:Prognosis; D012307:Risk Factors
chemical_list: C530104:CCND1 protein, human; D019938:Cyclin D1